-+ 0.00%
-+ 0.00%
-+ 0.00%

Novavax's Partners Receive Approvals For Nuvaxovid Formulation To Target SARS-CoV-2 XFG Variant

Benzinga·08/28/2026 12:34:51
Listen to the news

Novavax, Inc.'s (NASDAQ:NVAX) partners have received approvals for the Nuvaxovid™ formulation to target the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets including the U.S., European Union (EU) and Japan. These approvals position Novavax to continue earning royalties on net sales in these markets this season.